dry eye syndrome

Small-cap biotech Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) fell Tuesday morning following the release of clinical trial results. What Happened Aurinia said a mid-stage study that evaluated its dry eye syndrome treatment Voclosporin ophthalmic solution (VOS) -- 0.2 percent --...